Antibody microarray analysis of serum inflammatory cytokines in patients with calcific aortic valve disease

Bo Fu1, Yuhui Zhang1,2, Qingliang Chen1

  • 1Department of Cardiovascular Surgery, Tianjin Chest Hospital, Tianjin, China.

Insights

Calcific aortic valve disease (CAVD) involves inflammation. Researchers identified four key inflammatory markers, B-Lymphocyte Chemoattractant (BLC), Interleukin (IL)-12p40, monokine inducible by γ interferon (MIG), and Macrophage inflammatory protein (MIP)-1delta, as potential indicators for CAVD assessment.

Area of Science:

  • Cardiovascular Research
  • Immunology
  • Biomarker Discovery

Background:

  • Calcific aortic valve disease (CAVD) is a prevalent condition in the elderly, leading to aortic valve stenosis and significant mortality.
  • CAVD pathogenesis involves inflammation, apoptosis, lipid deposition, and matrix remodeling.
  • Current understanding necessitates novel diagnostic markers for CAVD.

Purpose of the Study:

  • To investigate and analyze the expression of serum inflammatory factors in patients with CAVD.
  • To identify potential serum biomarkers for the early detection and assessment of CAVD.

Main Methods:

  • A cohort of 258 patients was categorized into control, coronary artery disease (CAD), and CAVD groups.
  • Serum adipokine, cytokine, and chemokine profiles were analyzed using antibody microarray techniques.
  • Validation of key markers was performed using Real-time PCR, Western blot, and flow cytometry.

Main Results:

  • Significantly elevated levels of B-Lymphocyte Chemoattractant (BLC), Interleukin (IL)-12p40, monokine inducible by γ interferon (MIG), and Macrophage inflammatory protein (MIP)-1delta were observed in the CAVD group compared to control and CAD groups.
  • These four inflammatory markers were confirmed to originate from peripheral blood mononuclear cells.
  • The identified markers showed differential expression patterns relevant to CAVD.

Conclusions:

  • BLC, IL-12p40, MIG, and MIP-1delta demonstrate potential as reliable serum biomarkers for CAVD.
  • These findings may offer significant clinical implications for CAVD diagnosis and management.
  • Further research can explore the therapeutic targeting of these inflammatory pathways.
Abstract

Related Concept Videos

Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies01:22

Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies

The key clinical manifestations of Rheumatic heart disease (RHD) include several distinct cardiac symptoms.Carditis, a hallmark of acute rheumatic fever, involves inflammation of the heart's endocardium, myocardium, and pericardium. Chronic RHD often results from recurrent episodes of carditis. Its symptoms include the following:Murmurs are caused by valvular damage, especially to the mitral and aortic valves. Mitral stenosis or regurgitation is common, with characteristic heart murmurs...
310
Imaging Studies for Cardiovascular System VI: Calcium -Scoring CT01:25

Imaging Studies for Cardiovascular System VI: Calcium -Scoring CT

Calcium-Scoring CT ScanA calcium-scoring CT scan, also known as coronary artery calcium (CAC) scan, detects calcium deposits in the coronary arteries. This test assesses the risk of coronary artery disease (CAD), which can lead to cardiovascular events such as angina, heart failure, and sudden cardiac arrest.A calcium-scoring CT scan is generally recommended for individuals at intermediate risk of CAD without symptoms. It includes:Men aged 40-75 and women aged 50-75: Especially those with a...
269
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
11.3K